Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)

NCT00901849 is registered in ClinicalTrials.gov with Roger Packer as lead sponsor.

NCT NCT00901849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00901849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)
Lead sponsor
Roger Packer
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
October 31, 2012
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade gliomas